SCHEMBL1409448

SCHEMBL1409448

CC(NS(=O)(=O)CCCOCn1ccc(=O)[nH]c1=O)c1cccc(OC2CCCC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DUT P33316 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1409446 1.00 DUT (1.00) DUT
SCHEMBL1408766 0.96 DUT (1.00) DUT
SCHEMBL1408769 0.96 DUT (1.00) DUT
SCHEMBL1409562 0.93 DUT (1.00) DUT
SCHEMBL1409559 0.93 DUT (1.00) DUT
SCHEMBL1409881 0.92 DUT (1.00) DUT
SCHEMBL1409722 0.92 DUT (1.00) DUT
SCHEMBL1409725 0.92 DUT (1.00) DUT
SCHEMBL1409880 0.92 DUT (1.00) DUT
SCHEMBL1409758 0.91 DUT (1.00) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3693019-A1 ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR Taiho Pharmaceutical Co., Ltd. (JP) 2020-08-12 EP claimed
EP-2508185-B1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO LTD (JP) 2020-03-04 EP claimed
US-20190046639-A1 ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR, AND ANTITUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO., LTD (JP) 2019-02-14 US claimed
EP-3400963-A1 ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR, AND ANTI-TUMOR EFFECT ENHANCER Taiho Pharmaceutical Co., Ltd. (JP) 2018-11-14 EP claimed
US-20180134666-A1 NOVEL CRYSTAL OF URACIL COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-05-17 US claimed
US-20180110780-A1 AGENT FOR ALLEVIATING SIDE EFFECT OF ANTITUMOR DRUG TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-04-26 US claimed
EP-3290406-A1 NOVEL CRYSTAL OF URACIL COMPOUND Taiho Pharmaceutical Co., Ltd. (JP) 2018-03-07 EP claimed
EP-3290038-A1 AGENT FOR ALLEVIATING ADVERSE REACTION TO ANTITUMOR DRUG Taiho Pharmaceutical Co., Ltd. (JP) 2018-03-07 EP claimed
US-8883759-B2 Anti-tumor effect potentiator TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-11-11 US claimed
US-8530490-B2 Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-09-10 US claimed
EP-2295414-B1 URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2012-09-26 EP claimed
US-20120225838-A1 ANTI-TUMOR EFFECT POTENTIATOR TAIHO PHARMACEUTICAL CO., LTD. (JP) 2012-09-06 US claimed
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY TAIHO PHARMACEUTICAL CO., LTD. (JP) 2011-04-07 US claimed
EP-2295414-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2011-03-16 EP claimed
EP-4171549-B1 COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS NI LTD (GB) 2026-03-25 EP disclosed
US-20230263773-A1 COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2023-08-24 US disclosed
US-11612653-B2 Anti-tumor agent containing immunomodulator, and antitumor effect potentiator TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-03-28 US disclosed
EP-2295414-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2011-03-16 EP disclosed
EP-2295414-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2011-03-16 EP disclosed
WO-2009147843-A1 NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF 大鵬薬品工業株式会社 (JP) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134666-A1 NOVEL CRYSTAL OF URACIL COMPOUND UNG, UMPS, UGP2 DUT 9/4885
US-20180110780-A1 AGENT FOR ALLEVIATING SIDE EFFECT OF ANTITUMOR DRUG RPL6, SNRPA1, CCNT1 DUT 161/4885
US-20190046639-A1 ANTI-TUMOR AGENT CONTAINING IMMUNOMODULATOR, AND ANTITUMOR EFFECT POTENTIATOR NFATC1, DCLRE1B, DNASE1L3 DUT 67/4885
US-20230263773-A1 COMBINATION THERAPY WITH DEOXYURIDINE TRIPHOSPHATASE INHIBITORS TYMP, DUT, TYMS DUT 2/4885
US-20120225838-A1 ANTI-TUMOR EFFECT POTENTIATOR CCNT1, CCNA1, UPP1 DUT 305/4885
US-11612653-B2 Anti-tumor agent containing immunomodulator, and antitumor effect potentiator NFATC1, DCLRE1B, DNASE1L3 DUT 67/4885
US-20110082163-A1 NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY SNRPB2, SNRPA1, DUT DUT 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.